Johnson & Johnson (JNJ.US), a leading healthcare company, has announced the filing of a preliminary prospectus supplement with the Securities and Exchange Commission (SEC) under Rule 424(b)(5) for the issuance of a series of new senior unsecured notes. The notes, denominated in euros, are to be offered in three tranches with varying maturities and interest rates, which have yet to be determined. The interest on these notes will be paid annually, beginning in 2025. The notes will rank equally with Johnson & Johnson's other unsecured and unsubordinated debt. The company intends to list the notes on the New York Stock Exchange (NYSE) and expects trading to commence within 30 days post-issue. The proceeds from the sale of the notes are intended...Show More

Johnson & Johnson (JNJ.US), a leading healthcare company, has announced the filing of a preliminary prospectus supplement with the Securities and Exchange Commission (SEC) under Rule 424(b)(5) for the issuance of a series of new senior unsecured notes. The notes, denominated in euros, are to be offered in three tranches with varying maturities and interest rates, which have yet to be determined. The interest on these notes will be paid annually, beginning in 2025. The notes will rank equally with Johnson & Johnson's other unsecured and unsubordinated debt. The company intends to list the notes on the New York Stock Exchange (NYSE) and expects trading to commence within 30 days post-issue. The proceeds from the sale of the notes are intended for general corporate purposes, which may include funding the acquisition of Shockwave Medical, Inc., subject to customary closing conditions and regulatory approvals. The offering is subject to market conditions, and the completion of the offering is not contingent upon the completion of the acquisition. The date of the prospectus supplement is May 14, 2024.